Metastatic Colorectal Cancers Completed Phase 2 Trials for Panitumumab (DB01269)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00819780PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsTreatment
NCT00418938SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialTreatment
NCT01288339Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal CancerTreatment
NCT00332163Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based TherapyTreatment
NCT00327119Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal CancerTreatment
NCT00411450Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to TreatmentTreatment
NCT00475293Panitumumab in Combination With Irinotecan Chemotherapy as 2nd-line Therapy in Subjects With mCRCTreatment
NCT00508404Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal CancerTreatment
NCT00792363Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS MutationsTreatment
NCT00891930Study to Evaluate Mechanisms of Acquired Resistance to PanitumumabTreatment
NCT00958386Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)Treatment